The role of gut immune cells as a novel therapeutical target for cardiovascular disease

肠道免疫细胞作为心血管疾病新治疗靶点的作用

• 批准号: 520275106
• 负责人: Dr. Florian Kahles
• 金额: --
• 依托单位: Klinik für Kardiologie, Angiologie und Internistische Intensivmedizin (Med. Klinik I)
• 依托单位国家: 德国
• 项目类别: Independent Junior Research Groups
• 资助国家: 德国
• 项目状态: 未结题
• 来源: https://gepris.dfg.de/gepris/projekt/520275106?language=en
• 关键词: role; gut; immune; cells; novel

Cardiovascular disease continues to be the main cause of death worldwide, despite improved risk management and modern pharmacological therapies. Thus, novel therapeutic approaches have to be identified to reduce cardiovascular morbidity and mortality. Data from the last 2 decades have shown that inflammation plays an important role in cardiovascular disease such as atherosclerosis, myocardial infarction and heart failure. Next to the spleen and the bone marrow, the intestinal tract contains one of the largest immune cell reservoirs of our bodies. The role of gut immune cells for cardiovascular disease such as coronary artery disease, myocardial infarction and heart failure is largely unknown. In this project we will investigate the hypothesis whether intestinal immune cells could be identified as a novel therapeutical target for cardiovascular disease.

心血管疾病仍然是世界范围内的主要死亡原因，尽管风险管理和现代药物疗法有所改善。因此，必须找到新的治疗方法来降低心血管疾病的发病率和死亡率。过去20年的数据表明，炎症在动脉粥样硬化、心肌梗死和心力衰竭等心血管疾病中发挥着重要作用。仅次于脾和骨髓，肠道是我们身体中最大的免疫细胞库之一。肠道免疫细胞在冠心病、心肌梗死和心力衰竭等心血管疾病中的作用在很大程度上尚不清楚。在这个项目中，我们将调查肠道免疫细胞是否可以被确定为心血管疾病的新治疗靶点的假设。